IRL942 / IRLAB Therap - LARVOL DELTA

CORTICAL ENHANCEMENT - A NEW TREATMENT STRATEGY FOR SYMPTOMATIC TREATMENT AND SLOWING OF DISEASE PROGRESSION IN AD AND PD (ADPD 2025) - "Results Three cortical enhancer candidates have been selected and brought into clinical development: Pirepemat (IRL752), currently Phase 2b for prevention of falls in PD; IRL757, targeting PD-apathy, currently Phase 1 supported by MJFF; IRL942, targeting cognitive impairment, IND-enabling studies ongoing...Sustaining cortical neuronal activity may help maintain neuronal integrity and synaptic strength in connected subcortical areas, hence providing resilience from neurodegeneration. By directly strengthening cortico-subcortical circuitries, symptomatic effects including cognitive impairment, apathy, and falls could also be achieved."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders

IRLAB to Present Clinical and Preclinical Data at the AD/PD(TM) 2025: 19th International Conference on Alzheimer’s & Parkinson’s Diseases (Yahoo Finance) - "IRLAB Therapeutics...announced that it will showcase three abstracts at the AD/PD 2025: 19th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Vienna, Austria, April 1-5, 2025."

Clinical data • Alzheimer's Disease • Parkinson's Disease

IRLAB Therapeutics and the McQuade Center for Strategic Research and Development Enter into Agreement to Evaluate IRLAB’s Neuropsychiatric Programs IRL757 and IRL942 (BioSpace) - "IRLAB Therapeutics...IRLAB Therapeutics AB...today announced the signing of an agreement, with the McQuade Center for Strategic Research and Development, LLC (MSRD) (a member of the global Otsuka family of pharmaceutical companies), for MSRD to evaluate the neuropsychiatric compounds IRL757 and IRL942 under exclusivity. MSRD, which identifies and supports early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders, will exclusively evaluate and scientifically review the compounds, in exchange for providing IRLAB with an upfront payment. MSRD and IRLAB may, after the evaluation, agree to expand activities into a collaboration to continue to develop the compounds as pharmaceutical products."

Licensing / partnership • CNS Disorders • Parkinson's Disease

IRLAB updates on portfolio development milestones (Market Screener) - "IRLAB Therapeutics AB...today announced that the company has assessed the operational priorities for 2023....This will not impact the priority of the ongoing Phase IIb study of pirepemat in PD-Falls. The preclinical programs will proceed according to their respective plans; IRL757 will proceed to be Phase I ready by year-end 2023, IRL942 will be Phase I ready in H1 2024 and P003 candidate IRL1117 is just initiating its preclinical program with in-house R&D activities during 2023. The analysis of the completed Phase IIb study of mesdopetam continues, and it is anticipated that further data will be presented during H1 2023. The ongoing Phase IIb study of pirepemat...is active and progressing to plan with 28 of 39 planned sites in five European countries. Patient recruitment is slower than anticipated, and actions are ongoing to address this. The updated estimates predict the study will be fully recruited by the year-end 2023 with top-line results in H1 2024."

Enrollment status • New P1 trial • P2b data • Preclinical • CNS Disorders • Cognitive Disorders • Parkinson's Disease

IN VIVO SYSTEMS RESPONSE PROFILE MAPPING OF NOVEL CANDIDATE DRUGS IN DEVELOPMENT FOR TREATMENT OF SYMPTOMS RELATED TO CORTICAL IMPAIRMENT IN PARKINSON'S DISEASE (ADPD 2023) - " Treatment response profiles were generated for CNS reference compound s, including PD drugs, antidepressants, antipsychotics, psychostimulants, procognitive drugs, and candidate drugs IRL942, IRL757 and Phase IIb compound pirepemat. Systems response profiling/mapping of new candidate drugs suggest a pharmacological differentiation, IRL942 displaying a predominantly procognitive profile, IRL757 expressing additional effects suggesting effects also on symptoms linked to the underlying subcortical degeneration in PD, such as apathy, warranting clinical evaluation. This new class of compounds may have broad utility in neurocognitive disorders."

Preclinical • CNS Disorders • Cognitive Disorders • Developmental Disorders • Movement Disorders • Parkinson's Disease

IRL942 - A NOVEL COMPOUND WITH PROCOGNITIVE PROPERTIES ADRESSING CORTICAL IMPAIRMENT IN PARKINSON'S DISEASE (ADPD 2023) - "The most advanced candidate drug in this program, pirepemat, is currently in a clinical Phase 2b study addressing falls frequency in advanced Parkinson's disease...Results NOR: IRL942 significantly improved sub-chronic PCP-induced memory deficits with an efficacy similar to reference comparators risperidone or the D1-receptor agonist SKF38393...Specifically, IRL942 may promote short-term working memory, rule-learning flexibility, as well as executive function in models believed to exhibit translational validity towards man. These results are consistent with a procognitive action of IRL942, supporting current development towards cognitive impairment in PD."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease